Embecta

Embecta Cost of Goods Sold

The Cost of Goods Sold (COGS) of Embecta (EMBC) as of Oct 22, 2026 is 400.90 M USD. In the previous year, Cost of Goods Sold (COGS) was 394.20 M USD — a change of 1.70% (higher).

Cost of Goods Sold

400.90 MUSD

YoY

1.70%

Last updated:

Cost of Goods Sold (COGS) of Embecta is 2025 400.90 M USD. Cost of Goods Sold (COGS) of Embecta was 2024 394.20 M USD. It decreases by 1.70% higher compared to the previous year.

The Embecta Cost of Goods Sold history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cost of Goods Sold
Date
Cost of Goods Sold
Jan 1, 2019
323.00 M USD
Jan 1, 2020
323.00 M USD
Jan 1, 2021
365.00 M USD
Jan 1, 2022
354.60 M USD
Jan 1, 2023
370.90 M USD
Jan 1, 2024
394.20 M USD
Jan 1, 2025
400.90 M USD
The Embecta Cost of Goods Sold history
YEARCost of Goods SoldYoY
400.90 MUSD+1.70%
394.20 MUSD+6.28%
370.90 MUSD+4.60%
354.60 MUSD-2.85%
365.00 MUSD+13.00%
323.00 MUSD0.00%
323.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Cost of Goods Sold (COGS) of Embecta is 400.90 M USD in 2025.

Cost of Goods Sold (COGS) of Embecta changed from 394.20 M USD to 400.90 M USD, representing a 1.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cost of Goods Sold (COGS) Embecta since 2006 – with annual values, charts, and detailed analysis.

COGS represents the direct costs attributable to the production of goods sold. It includes material and labor costs directly tied to the product.

Cost of Goods Sold (COGS)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cost of Goods Sold (COGS)'s Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Embecta

All Key Metrics — Embecta